clinical trial · NCT07140900
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)XaluritamigDarolutamideAbiraterone
brief summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
started
Oct 7, 2025
primary completion
Oct 27, 2027
completion
Oct 29, 2029
last updated
Nov 12, 2026
official title
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol